The difference between Lantus and Lantus is that Lantus contains 100U of insulin glargine per milliliter, while Lantus contains 300U of insulin glargine per milliliter.
Many patients with diabetes know Lantus (insulin glargine), an excellent long-acting insulin. Recently, the company has launched a better long-acting insulin called Unisex.
Latus is an upgraded product of Lantus, and some people call it the third generation basal insulin. First generation, intermediate-acting human insulin. The second generation, long-acting insulin analogues, including Lantus and Nobel, have the same anti-hyperglycemic effect as intermediate-acting insulin, but significantly reduce hypoglycemia. Therefore, in many countries, only patients with conditions prone to hypoglycemia can use intermediate-acting insulin. Only long-acting insulin analogues can be prescribed because of the high price of the latter. Third generation, concentrated insulin glargine (Lexus) and insulin degludec (Novoda).
The new technology enables the drug to have a higher concentration and is slowly released in the body after subcutaneous injection. There will be no concentration peak of the drug and it will last longer. Compared with Lantus, the efficacy is similar, but the side effects of hypoglycemia are smaller.
What’s even better is that for people at high risk of hypoglycemia, such as those over 70 years old and patients with chronic renal failure, Latusi is better than Lantus and previously launched products without the risk of hypoglycemia. Insulin degludec is more effective.
Although insulin is not the first-line drug for the treatment of type 2 diabetes, diabetic patients with acute complications of diabetes, before and after diabetes surgery, and with declining pancreatic function still prefer insulin treatment, especially long-acting insulin.
In fact, as far as current technology is concerned, the efficacy of several long-acting insulins is equivalent. The difference lies in some differences in pharmaceutical technology. The so-called details determine success or failure. The new insulins work longer and have a lower risk of hypoglycemia, which is the main reason they were approved for use.